Servier, MiNA Partner to Develop Treatments for Neurological Diseases

French drugmaker Servier and UK-based MiNA Therapeutics have teamed up to develop small activating RNA (saRNA) therapies for neurological disorders.

Under the deal, MiNA will use its saRNA platform to identify possible treatments, while Servier will oversee development of any candidates identified and will hold global rights. Financial details of the agreement were not disclosed.

Servier is also expanding its cancer drug portfolio. Last month, the company announced that it would purchase Agios Pharmaceuticals’ oncology business in a deal worth up to $2 billion.